Literature DB >> 10676646

Imaging brain tumor proliferative activity with [124I]iododeoxyuridine.

R G Blasberg1, U Roelcke, R Weinreich, B Beattie, K von Ammon, Y Yonekawa, H Landolt, I Guenther, N E Crompton, P Vontobel, J Missimer, R P Maguire, J Koziorowski, E J Knust, R D Finn, K L Leenders.   

Abstract

Iododeoxyuridine (IUdR) uptake and retention was imaged by positron emission tomography (PET) at 0-48 min and 24 h after administration of 28.0-64.4 MBq (0.76-1.74 mCi) of [124I]IUdR in 20 patients with brain tumors, including meningiomas and gliomas. The PET images were directly compared with gadolinium contrast-enhanced or T2-weighted magnetic resonance images. Estimates for IUdR-DNA incorporation in tumor tissue (Ki) required pharmacokinetic modeling and fitting of the 0-48 min dynamically acquired data to correct the 24-h image data for residual, nonincorporated radioactivity that did not clear from the tissue during the 24-h period after IUdR injection. Standard uptake values (SUVs) and tumor:brain activity ratios (Tm:Br) were also calculated from the 24-h image data. The Ki, SUV, and Tm/Br values were related to tumor type and grade, tumor labeling index, and survival after the PET scan. The plasma half-life of [124I]IUdR was short (2-3 min), and the arterial plasma input function was similar between patients (48 +/- 12 SUV*min). Plasma clearance of the major radiolabeled metabolite ([124I]iodide) varied somewhat between patients and was markedly prolonged in one patient with renal insufficiency. It was apparent from our analysis that a sizable fraction (15-93%) of residual nonincorporated radioactivity (largely [124I]iodide) remained in the tumors after the 24-h washout period, and this fraction varied between the different tumor groups. Because the SUV and Tm:Br ratio values reflect both IUdR-DNA incorporated and exchangeable nonincorporated radioactivity, any residual nonincorporated radioactivity will amplify their values and distort their significance and interpretation. This was particularly apparent in the meningioma and glioblastoma multiforme groups of tumors. Mean tumor Ki values ranged between 0.5 +/- 0.9 (meningiomas) and 3.9 +/- 2.3 microl/min/g (peak value for glioblastoma multiforme, GBM). Comparable SUV and Tm:Br values at 24 h ranged from 0.13 +/- 0.03 to 0.29 +/- 0.19 and from 2.0 +/- 0.6 to 6.1 +/- 1.5 for meningiomas and peak GBMs, respectively. Thus, the range of values was much greater for Ki (approximately 8-fold) compared with that for SUV (approximately 2.2-fold) and Tm:Br (approximately 3-fold). The expected relationships between Ki, SUV, and Tm:Br and other measures of tumor proliferation (tumor type and grade, labeling index, and patient survival) were observed. However, greater image specificity and significance of the SUV and Tm:Br values would be obtained by achieving greater washout and clearance of the exchangeable fraction of residual (background) radioactivity in the tumors, i.e., by increased hydration and urinary clearance and possibly by imaging later than 24 h after [124I]IUdR administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676646

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Use of positron emission tomography in anticancer drug development.

Authors:  Eric O Aboagye; Patricia M Price
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

2.  Does (124)Iodo-deoxyuridine measure cell proliferation in NSCLC? Initial investigations with PET imaging and radio-metabolite analysis.

Authors:  Heather Williams; Peter Julyan; Malcolm Ranson; Jamal Zweit; James Gillies; David Hastings
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02       Impact factor: 9.236

3.  Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

Authors:  Sven N Reske; Sandra Deisenhofer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

4.  Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report.

Authors:  J S Lewis; M J Welch; L Tang
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 2.346

5.  5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.

Authors:  Timothy J Kinsella; Michael T Kinsella; Yuji Seo; Gregory Berk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

6.  Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system.

Authors:  Rebecca A Gregory; Claire A Hooker; Mike Partridge; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-14       Impact factor: 9.236

Review 7.  Molecular imaging in clinical trials.

Authors:  Debra Josephs; James Spicer; Michael O'Doherty
Journal:  Target Oncol       Date:  2009-09-21       Impact factor: 4.493

Review 8.  Auger radiation targeted into DNA: a therapy perspective.

Authors:  Franz Buchegger; Florence Perillo-Adamer; Yves M Dupertuis; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-08       Impact factor: 9.236

9.  Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridine.

Authors:  Florence Perillo-Adamer; Angelika Bischof Delaloye; Céline S Genton; Andreas O Schaffland; Yves M Dupertuis; Franz Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

10.  Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment.

Authors:  Chun-Yi Wu; Lin-Shan Chou; Pei-Chia Chan; Chung-Hsien Ho; Ming-Hsien Lin; Chih-Chieh Shen; Ren-Shyan Liu; Wuu-Jyh Lin; Hsin-Ell Wang
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.